GenScript ProBio vs Illumina
Side-by-side comparison of AI visibility scores, market position, and capabilities
GenScript ProBio is the CDMO subsidiary of GenScript Biotech, offering gene synthesis, biologics development, cell therapy manufacturing (CAR-T), and life science CRO services; publicly listed on the Hong Kong Stock Exchange (HK: 1548);
About
GenScript ProBio is the contract development and manufacturing organization (CDMO) business unit of GenScript Biotech Corporation, one of the world's largest life science research and manufacturing companies. GenScript ProBio provides end-to-end biologics and cell and gene therapy development services, leveraging GenScript's foundational strength in gene synthesis — the company's proprietary gene synthesis technology is the backbone of its CDMO offering and enables highly accurate, rapid construction of complex genetic sequences for therapeutic applications. Services span plasmid and viral vector manufacturing, CAR-T and other cell therapy production, monoclonal antibody development, and comprehensive CRO services for early-stage drug discovery.
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
About
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
Key Details
Capabilities & Ecosystem
Also Compare
GenScript ProBio vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.